Substituting Blood-Based Biomarkers for Imaging Measures in Alzheimer’s Disease Studies: Implications for Sample Size and Bias
While blood-based biomarkers are lower cost and easier to collect than neuroimaging measures, their use as proxies for AD pathology may introduce substantial methodological challenges, depending on the p-tau isoform. Consideration of the sample sizes they necessitate and their potential for bias is critical for the design and interpretation of studies employing these biomarkers.
Authors
- Michelle R. Caunca (ORCID: https://orcid.org/0000-0002-5177-9048)
- Sarah F. Ackley (ORCID: https://orcid.org/0000-0003-0181-6063)
- Eleanor Hayes-Larson
- for the Alzheimer’s Disease Neuroimaging Initiative
- Seo-Eun Choi
- Renaud La Joie
- Emily H Trittschuh
- Paul K Crane
- Shubhabrata Mukherjee
Institutions
- University of Southern California (US)
- University of California, San Francisco (US)
- University of Washington (US)
- Brown University (US)
- University Memory and Aging Center (US)
Publication Details
- Journal
- The Journals of Gerontology Series A
- Published
- 2026-03-11
- DOI
- https://doi.org/10.1093/gerona/glag068
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00